Merck and NanoString Technologies, Inc. entered a clinical research collaboration to develop an assay to optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in multiple tumor types. The collaboration will utilize NanoString’s nCounter Analysis System to optimize gene expression signatures as part of the clinical development program for KEYTRUDA. “Our commitment to advancing the science of immu...